Drugs / zoptarelin doxorubicin
zoptarelin doxorubicin
also known as
AEZS-108 · AN-152 · AN-52 · D-81858 · ZEN-008 · ZOPTARELIN DOXORUBICIN ACETATE · Zoptarelina doxorubicina · Zoptareline doxorubicine
Other / unclassified targets GNRHR via activation
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01240629 | Nov 2010 → Feb 2017 | hormone-resistant prostate carcinoma | University of Southern California | Completed | No outcome recorded |
| Phase 1/2 | NCT01234519 | Nov 2010 → Nov 2014 | urothelial carcinoma | AEterna Zentaris | Terminated | No outcome recorded Stop: Enrollment |
| Phase 22 trials | ||||||
| Phase 2 | NCT01698281 | Dec 2012 → Aug 2014 | breast cancer | AEterna Zentaris | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00569257 | Dec 2007 → Jul 2011 | endometrial cancer, ovarian cancer | AEterna Zentaris | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01767155 | Apr 2013 → Jan 2017 | endometrial cancer | AEterna Zentaris | Completed | Missed primary |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zoptarelin doxorubicin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01767155 ↗ |
| Known as | AEZS-108 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01234519 ↗ |
| Known as | AN-152 | “An experimental drug called AN-152 (also known as AEZS-108) will be used.” NCT01240629 ↗ |
| Known as | AN-52 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544954 ↗ |
| Known as | D-81858 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544954 ↗ |
| Known as | ZEN-008 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544954 ↗ |
| Known as | ZOPTARELIN DOXORUBICIN ACETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544954 ↗ |
| Known as | Zoptarelina doxorubicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544954 ↗ |
| Known as | Zoptareline doxorubicine | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544954 ↗ |
| Action | Activate | “Gonadotropin-releasing hormone receptor agonist” CHEMBL3544954 ↗ |
| Modality | Other / unclassified | “AEZS-108 is an investigational drug, combining luteinizing hormone-releasing hormone (LHRH), an hormone and doxorubicin (a drug approved to treat different types of cancer).” NCT01234519 ↗ |
| Route | Intravenous | “intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles” NCT00569257 ↗ |
| Target | GNRHR | “Gonadotropin-releasing hormone receptor agonist” CHEMBL3544954 ↗ |